

Press Release

Kraków, April 19, 2022.

The tech company MedApp applies to list 209 million shares

MedApp, an innovative player in the field of advanced medical technologies (SaMD - *software as a medical device*), on April 14, 2022 applied to the Management Board of the Warsaw Stock Exchange for the introduction of all previously unlisted shares to trading on the NewConnect market.

“Due to the high volatility of the capital market, we have temporarily suspended the prospectus procedure, but at the same time we want to introduce not yet admitted shares to trading on NewConnect,” says **Krzysztof Mędrała, CEO of MedApp S.A.**

MedApp has applied to the Board of the Warsaw Stock Exchange for the listing of nearly 209 million series D, E, F and G shares, which have so far remained outside the stock market. That's 83.5% of the total 250 million shares into which the company's capital is divided.

MedApp consistently leverages the international sales potential of its 3D holographic visualization and digital medicine technology solutions. The company has grown dynamically, and as a result is not only entering new markets and expanding its product portfolio, but also rapidly increasing its current financial performance: MedApp doubled its revenue and profits in 2021.

Geographic expansion and product portfolio development

Since 2021, MedApp has been signing foreign distribution agreements and expanding sales channels in Poland. Concluding distribution agreements with new partners has also resulted in entry into the Brazilian market. In March 2022, MedApp began the process of registering its first foreign company, which will be responsible for business development in the German, Austrian and Swiss markets. MedApp S.A., in cooperation with Parexel, is preparing to apply for certification for CarnaLife Holo with the FDA, which is a necessary condition to enter the world's largest medical market, the United States.

MedApp develops functionality for solutions based on 3D holographic visualization (CarnaLife Holo) and digital medicine platform, CarnaLife System. In the first quarter of 2022, MedApp received a grant from the National Center for Research and Development to create a mixed reality navigation tool for physicians (CarnaLife Holo MedNav). The company has also signed an agreement with Helimed Diagnostic Imaging network to develop Radiology Information System (RIS) software to store and manage medical imaging data, which will ultimately be integrated with the CarnaLife System platform. After the implementation of RIS in the Helimed network, MedApp plans (from the second quarter of 2023) to launch the sales of this solution in other diagnostic imaging facilities in Poland.

OFFICE IN KRAKOW


Armii Krajowej 25
30-150 Krakow
Poland

COMPANY DATA

MedApp S.A.
Tax ID: 7010264750
Registration ID: 0000365157
Statistical ID: 142641690

CONTACT

E-mail: biuro@medapp.pl
Phone no.: +48 533 306 117
www.MedApp.pl



MedApp is an innovative technology company, so its potential is naturally enhanced by the appreciation of the technologies by independent experts. In addition to numerous accolades, last October, Google selected MedApp for its accelerator program as one of the top fifteen medtech startups in Europe. In February this year, MedApp won the OVHcloud competition for medtech companies.

Contact for media

Adrian Boczkowski
P&L Investor Relations
a.boczkowski@pandl.pl
+48 506 324 456

MedApp is a publicly traded technology company offering innovative, unique software solutions for diagnostic imaging and next-generation digital medicine (medtech) services based on artificial intelligence, mixed reality and 3D imaging solutions. Its key products are: **CarnaLife Holo**, **CarnaLife System**, **HoloComm** and **Digital Clinic**. The Company is supported by a Scientific Council consisting of recognized experts in the field of medical innovation. MedApp also cooperates with international technology and medical leaders such as Google, Microsoft, or GE Healthcare, providing its customers with secure storage, analysis and visualization of large amounts of data.

CarnaLife Holo is a certified innovative technology that supports the planning and execution of complex medical procedures. With the help of Microsoft's HoloLens 2 goggles, the doctor sees in real 3D space a hologram that reflects the imaged anatomical area. The physician is free to interact with the displayed hologram. CarnaLife Holo is present in several dozen medical facilities in Poland and abroad, and it has already been used in over 250 medical procedures of different specializations.

CarnaLife System is an advanced digital medicine platform that allows a physician to assess and monitor the health of their patients and conduct consultations at any time of the day and at any place. The system is supported by more than 20 remote measurement devices. Examination results are analyzed 24/7 using AI algorithms and Big Data analytics. The system has been implemented in several dozen medical facilities. On the basis of this solution, the **Digital Clinic** was created, which is a product aimed directly at patients and individual users.

HoloComm is a platform for remote 3D presentation of products and data using Microsoft HoloLens 2 glasses. The software can be used in industry, medicine and education.

The Company is dynamically developing its business and records recurring positive quarterly results. **MedApp S.A. shares are listed on the NewConnect market in Warsaw and on the Börse Frankfurt**. More information about the company and the innovations we are developing is available at www.medapp.pl and [LinkedIn](#).

We also encourage you to watch the videos:

- [webinar with CEO Krzysztof Mędrała - WSE Innovation Day 2021](#)
- [Operation Hologram / "W głowie się nie mieści by Chajzer&Kawęcki"](#)

OFFICE IN KRAKOW

Armii Krajowej 25
30-150 Krakow
Poland

COMPANY DATA

MedApp S.A.
Tax ID: 7010264750
Registration ID: 0000365157
Statistical ID: 142641690

CONTACT

E-mail: biuro@medapp.pl
Phone no.: +48 533 306 117
www.MedApp.pl

